3 ms·
Novo Nordisk Falls Most on Record After New Weight Drug Disappoints
- loeg 2y agoPartially/mostly legible archive.is link: https://archive.is/Pp4fT https://archive.is/Pp4fT Or, no paywall: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-next-gen-obesity-drug-cagrisema-achieves-lower-weight-loss-than-2024-12-20/ https://www.reuters.com/business/healthcare-pharmaceuticals/... > The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Contrasted with Lilly's already approved Zepbound (tirzepatide): > Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials.
- deleted 2y ago[deleted]
- GenerWork 2y agoArticle also talked about Lilly, which is important because they're developing a triple agonist called retatrutide. It's currently in trials, and if it succeeds, you'll see Novo stock fall even further while Lilly stock will soar.
- loeg 2y agoFWIW it doesn't seem to be much more effective than tirzepatide: > Lilly is also working on a next-generation medicine, called retatrutide, which helped people lose up to about 24% of their weight in a mid-sized study last year. (Tirzepatide saw 22 or 23%.) Unclear to me if or how the retatrutide numbers might improve.
- GenerWork 2y agoI'd bet that it'll exceed tirzepatide by a bit, but they'll hype up the triple agonist action. What's wild is that there's companies doing research for quadruple agonists! Found this[0] company that's looking at one such agonist right now. [0] https://www.biomedind.com/NA-931.html https://www.biomedind.com/NA-931.html